---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004613"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:33:20.220539+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Indaptus appoints Robert Martell, M.D., Ph.D. to Board of Directors

## Summary
- Board size increased to nine; Martell appointed Class I director effective Feb 13, 2023.
- Annual retainer of $50,000 for Board service; standard indemnification agreement.
- Received initial option for 20,000 shares at $1.71/share (fair market value on grant date).
- Annual equity award up to $75,000 value (Black-Scholes) vesting on first anniversary or upon change of control.

## SEC filing metadata
- accession: 0001493152-23-004613
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/0001493152-23-004613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004613
- JSON: https://secwatch.observer/filing/0001493152-23-004613.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004613.txt

## Key facts
- Executive change
  Robert Martell was appointed as Class I director at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/0001493152-23-004613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.